Advertisement
Advertisement
CCCC
C4 Therapeutics, Inc.
2.95
USDSponsored
-0.03
-1.01%
May 08, 15:58 UTC -4
Closed
Pre-Market
3.04
+0.09
+3.22%
CCCC Earnings Reports
Positive Surprise Ratio
CCCC beat 14 of 22 last estimates.
64%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$3.06M
/-$0.37
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q2 25 (Revenue/ EPS)
-52.65%
/--
C4 Therapeutics, Inc. earnings per share and revenue
On May 05, 2026, CCCC reported earnings of -- USD per share (EPS) for Q1 26, -- the estimate of -0.37 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 3.40 million, with a --% difference.
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.37 USD, with revenue projected to reach 3.06 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Iovance Biotherapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.19
Surprise
-24.35%
Corvus Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.15
Surprise
-2.95%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
Ginkgo Bioworks Holdings, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.09
Actual
-$1.28
Surprise
-17.35%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Codexis, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.13
Actual
-$0.10
Surprise
+28.26%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
PTC Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.47
Actual
-$0.03
Surprise
+93.75%
Scholar Rock Holding Corporation Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.81
Actual
-$0.83
Surprise
-1.62%
FAQ
What were C4 Therapeutics, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, C4 Therapeutics, Inc. reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to C4 Therapeutics, Inc.'s Q1 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is C4 Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for C4 Therapeutics, Inc.'s next earnings report?
Based on 6
analysts, C4 Therapeutics, Inc. is expected to report EPS of -$0.37 and revenue of $3.06M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement